8-K: Nuo Therapeutics and Smith+Nephew Amend Distribution Agreement to Include Interim Sales Agency

Nuo Therapeutics and Smith+Nephew have amended their distribution agreement to include an interim sales agency arrangement for Nuo Aurix branded products.

Summary

• Nuo Therapeutics, Inc. and Smith+Nephew, Inc. entered into Amendment No. 1 to their Distribution Agreement on May 14, 2025.
• The amendment establishes an interim sales agency arrangement where Smith+Nephew will act as a sales agent for Nuo Aurix branded products to specific Smith+Nephew customers.
• Smith+Nephew will receive a commission on net sales of Nuo branded products sold to their customers.
• The interim sales agency arrangement will end on December 31, 2025, or earlier if Smith+Nephew provides 30 days' written notice of termination.
• The original Distribution Agreement, which involves Nuo supplying Smith+Nephew with a private label of Nuo's Aurix brand product with minimum purchase commitments for five years, remains in effect.
• Details of the amendment will be available in Nuo's Quarterly Report on Form 10-Q for the three months ended June 30, 2025.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. It expands the distribution reach of Nuo's products but the interim nature of the sales agency agreement and the lack of specific financial details temper the enthusiasm.

Positives

• The interim sales agency agreement could increase sales of Nuo Aurix products through Smith+Nephew's customer base.
• The existing distribution agreement ensures a consistent revenue stream for Nuo Therapeutics through private label supply to Smith+Nephew.

Negatives

• The interim sales agency arrangement is temporary, ending on December 31, 2025, or earlier if terminated by Smith+Nephew.
• The commission structure may impact Nuo's profit margins on sales made through Smith+Nephew's sales agency.

Risks

• The termination of the interim sales agency agreement could negatively impact Nuo's sales if a replacement strategy is not in place.
• The reliance on Smith+Nephew for distribution exposes Nuo to risks associated with Smith+Nephew's business decisions and performance.
• Confidential information omitted from the filed agreements could be material to understanding the full scope of the arrangement.

Future Outlook

The amendment provides an interim sales agency arrangement until December 31, 2025, or earlier if terminated by Smith+Nephew, while the original distribution agreement continues for an initial term of five years.

Management Comments

• David E. Jorden, Chief Executive and Chief Financial Officer of Nuo Therapeutics, signed the report on behalf of the company.

Industry Context

Distribution agreements and sales agency arrangements are common in the medical device industry to expand market reach and leverage existing sales networks. Smith+Nephew is a major player in the advanced wound management market, so this agreement allows Nuo to tap into their established customer base.

Comparison to Industry Standards

• Similar distribution agreements are common in the medical device industry, where companies like Medtronic, Johnson & Johnson, and Stryker often partner with smaller firms to distribute their products.
• Commission rates for sales agency agreements in the medical device sector typically range from 5% to 20% of net sales, depending on the product and market.
• Five-year distribution agreements with minimum purchase commitments are standard practice to ensure a stable supply chain and revenue stream.

Stakeholder Impact

• Shareholders may see a positive impact from increased sales through Smith+Nephew's sales agency.
• Customers of Smith+Nephew will have access to Nuo Aurix products.
• Nuo's employees may benefit from increased sales and production.

Next Steps

• Nuo will file the Amendment as an exhibit to its Quarterly Report on Form 10-Q for the three months ended June 30, 2025.
• Smith+Nephew will begin acting as a sales agent for Nuo Aurix products to their customers.
• Nuo and Smith+Nephew will continue to operate under the terms of the original Distribution Agreement.

Key Dates

Keywords

Distribution Agreement, Smith+Nephew, Nuo Therapeutics, Sales Agency, Aurix, Amendment